The consensus estimates are gathered from sell-side analysts covering Lundbeck shortly before our Q1 report in May 2008.
|
DKK millions
|
Q1 2008
|
2008
|
2009
|
2010
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Group revenue, reported (average)
|
      2.716
|
  11.287
|
  12.071
|
  12.840
|
|
High
|
         2.753
|
    11.372
|
  12.346
|
    13.230
|
|
Low
|
         2.696
|
  11.195
|
   11.850
|
    12.439
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Group revenue excl. milestone payments (average)
|
      2.721
|
  11.280
|
  12.054
|
  12.789
|
|
High
|
        2.753
|
     11.372
|
  12.346
|
    13.230
|
|
Low
|
         2.702
|
    11.173
|
  11.801
|
    12.439
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Other pharmaceuticals (average)
|
        415
|
    1.593
|
    1.485
|
    1.396
|
|
High
|
            426
|
      1.660
|
   1.563
|
  1.512
|
|
Low
|
            405
|
  1.525
|
  1.349
|
     1.216
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Cipralex (average)
|
        1.105
|
    4.614
|
    5.023
|
    5.391
|
|
High
|
 1.123
|
  4.700
|
5.176
|
5.651
|
|
Low
|
     1.080
|
4.544
|
 4.908
|
   5.147
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Ebixa (average)
|
        446
|
    1.894
|
    2.108
|
    2.245
|
|
High
|
    459
|
1.926
|
  2.190
|
2.402
|
|
Low
|
    428
|
1.865
|
2.045
|
  2.175
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Azilect (average)
|
           51
|
      242
|
      324
|
      392
|
|
High
|
 55
|
        254
|
        351
|
        465
|
|
Low
|
          48
|
         232
|
         287
|
         328
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Serdolect (average)
|
             13
|
        66
|
      106
|
      163
|
|
High
|
                15
|
         80
|
         149
|
         282
|
|
Low
|
                10
|
           53
|
           71
|
           85
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Circadin (average)
|
                - Â
|
        35
|
        91
|
      174
|
|
High
|
             - Â
|
       60
|
  130
|
        234
|
|
Low
|
                   -   Â
|
    16
|
      48
|
 120
|
|
Income from Lexapro sales (average)
|
        631
|
    2.578
|
    2.594
|
    2.678
|
|
High
|
         648
|
     2.734
|
     2.876
|
    3.048
|
|
Low
|
    610
|
    2.476
|
  2.401
|
   2.440
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Profit from operations (EBIT), reported (average)
|
        699
|
    2.864
|
    3.169
|
    3.466
|
|
High
|
             732
|
      2.912
|
   3.305
|
3.666
|
|
Low
|
             666
|
  2.831
|
  3.042
|
 3.256
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Profit from operations (EBIT), excl. milestone payments (average)
|
        699
|
    2.864
|
    3.169
|
    3.466
|
|
High
|
             732
|
      2.912
|
  3.305
|
  3.666
|
|
Low
|
             666
|
    2.831
|
  3.042
|
 3.256
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Net financial income (average)
|
              1
|
        10
|
        28
|
        78
|
|
High
|
                13
|
          51
|
           70
|
      139
|
|
Low
|
          (15)
|
      (37)
|
 (21)
|
        50
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Tax on profit (average)
|
        30.0%
|
    30,0%
|
    30,0%
|
    30,0%
|
|
High
|
    30,1%
|
    30,0%
|
30,0%
|
     30,0%
|
|
Low
|
   30.0%
|
30,0%
|
  30,0%
|
    30,0%
|
|
Â
|
Â
|
Â
|
Â
|
Â
|
|
Earnings per share (average), crowns
|
        2.45
|
    10,26
|
    11,53
|
    13,01
|
|
High
|
             2.53
|
      10,51
|
    12,18
|
      14,13
|
|
Low
|
               2.32
|
      10,08
|
     11,08
|
      12,22
|
|
